The phase 4 study of the tacrolimus ointment 0.03% in Infant and toddler patients with Atopic dermatitis

The phase 4 study of the tacrolimus ointment 0.03% in Infant and toddler patients with Atopic dermatitis -Long-term study-

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230181

Enrollment

Registered

2023-06-25

Start date

2023-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Apply appropiriate amount of the tacrolimus ointment 0.03% once or twice daily to the affected area

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mild or higher atopic dermatitis aged between 6 months and 2 years.

Exclusion criteria

Exclusion criteria: - medical history and/or concomitant disease of malignancy, serious allegies, allegy to tacrolimus or skin hypersensitivity to topical medicinal products. - serious complication of any cardiac, hepatic, renal, pulmonary, hematological disorder etc, which is considered inappropriate to participate in the trial by investigators.

Design outcomes

Primary

Measure	Time frame
EASI	—

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026